Mylan Launches Generic Prandin® Tablets
January 23, 2014
Displayed with permission from PR Newswire
PITTSBURGH, Jan. 23, 2014 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk’s Prandin ®, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.(1) The company received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.
Read More… http://repubhub.icopyright.net/freePost.act?tag=3.7537%3Ficx_id%3D7443088